IL28B

(redirected from IFNL4)

IL28B

A gene on chromosome 19q13.13 that encodes interleukin-28B, an immunomodulatory cytokine which upregulates MHC class-I antigen expression. It has potent antiviral activity and has antitumour activity. IL28B is a ligand for the heterodimeric class-II cytokine receptor composed of IL10RB and IL28RA, which is thought to act via the JAK-STAT pathway. Difference between the two isoforms of IL28 (IL28A and IL28B) remains unclear.
Mentioned in ?
References in periodicals archive ?
IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
Objective: To describe the risk factors for infection, complications, treatment received and response in Puerto Ricans with HCV attending gastroenterology clinics at UPR-MSC, and the prevalence of single nucleotide polymorphisms (SNPs) in IFNL3 and IFNL4 in this population.
SNP frequencies of IFNL4 locus SS469415590 were 26% (TT/TT), 48% (TT/[DELTA]G), and 26% ([DELTA]G/[DELTA]G).
Key words: Hepatitis C, IFNL3, IFNL4, Single Nucleotide Polymorphisms, Puerto Ricans, Hispanics
Objetivos: El proposito del estudio fue describir factores de riesgo, complicaciones, tratamiento, respuesta y prevalencia de polimorfismos de nucleotidos sencillos (PNS) en IFNL3 e IFNL4 en puertorriquenos con hepatitis C en las clinicas de Gastroenterologia- UPR.
Results showed that IFNL4 protein could be generated in IFNL4-[DELTA]G carriers and not in IFNL4-TT homozygote carriers.
The aims of this study were to describe the demographics and clinical characteristics of as well as the genetic polymorphisms in IFNL3 (rs12979860 and rs8099917) and IFNL4 (ss469415590) in a cohort of Hispanic patients chronically infected with HCV.
Frequency distributions (frequency and percent) were generated to describe the clinical characteristics and prevalence of IFNL3 and IFNL4 SNPs among HCV-infected patients.
Previous studies have shown an association between specific SNPs near IFNL3 or IFNL4 and the viral load exhibited by an HCV-infected patient, the frequency of SVR following completion of treatment, or liver histology (29, 39).
Future studies in our study group of HCV-infected Hispanics should aim to assess the SVR according to treatment, controlling for IFNL3 and IFNL4 SNPs.